Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
NCT04521348
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
103
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
DRUG:
multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Sponsor
Fudan University